SCHEDULE: Farb Maintains 7.7% Stake in Artelo Bio After Offering

Daniel S. Farb has updated his beneficial ownership in Artelo Biosciences, Inc. to 7.7% following a recent underwritten public offering.

Summary

• Daniel S. Farb beneficially owns 153,003 shares of Artelo Biosciences, Inc. common stock.
• This represents approximately 7.7% of the company's outstanding shares.
• The shares were acquired using personal funds, with an aggregate purchase price of approximately $850,036, excluding brokerage commissions.
• Farb also holds 11,299 warrants with an exercise price of $10.00 per share, expiring in June 2030.
• Due to a 4.99% beneficial ownership limitation, Farb currently cannot exercise these warrants and does not beneficially own the underlying shares.
• The calculation of the percentage ownership is based on 1,555,493 shares outstanding as of September 16, 2025, plus 441,210 shares issued in an October 1, 2025 underwritten offering.
• The remaining 3 shares underlying previously held $5.82 warrants have been delivered, and Farb no longer holds these warrants.

Sentiment

Score: 6

Explanation: The filing indicates a significant shareholder, Daniel S. Farb, maintains a substantial 7.7% stake in Artelo Biosciences, even after a dilutive underwritten offering. This continued commitment, backed by personal funds, suggests confidence in the company. However, the beneficial ownership limitation on warrants and the dilutive effect of the offering temper the overall positive sentiment.

Positives

• A significant individual investor, Daniel S. Farb, maintains a substantial 7.7% stake in Artelo Biosciences, indicating continued confidence.
• The investor has committed personal funds totaling approximately $850,036 to acquire shares.

Negatives

• The beneficial ownership limitation of 4.99% prevents the reporting person from immediately exercising 11,299 warrants, potentially limiting their ability to increase their stake without prior notice.
• The company recently conducted an underwritten offering, which typically results in dilution for existing shareholders.

Risks

• The beneficial ownership limitation on the $10 Warrants restricts the reporting person's ability to increase their stake beyond 4.99% without providing 61 days' prior notice to the Issuer, potentially impacting their flexibility.

Future Outlook

NA

Industry Context

This Schedule 13D amendment provides an update on a significant shareholder's position in Artelo Biosciences, a company likely operating in the biotechnology or life sciences sector given its name. The context of a recent underwritten offering suggests the company is raising capital, a common activity for development-stage biotech firms to fund research, clinical trials, or operations. The investor's continued significant stake, even after dilution from the offering, could be viewed as a positive signal within the industry.

Stakeholder Impact

• Shareholders: Existing shareholders experienced dilution due to the underwritten offering. However, the continued significant stake of Daniel S. Farb may provide a level of investor confidence.
• Company: The capital raise from the underwritten offering provides additional funds for company operations, which could benefit its strategic initiatives.

Key Dates

Recommendation

While the maintenance of a significant stake by a key investor like Daniel S. Farb can be seen as a positive signal, the recent underwritten offering caused dilution for existing shareholders. The beneficial ownership limitation on the warrants also adds a layer of complexity for the reporting person's future potential stake increase. Without further financial or operational updates from Artelo Biosciences, the information in this Schedule 13D amendment primarily confirms an ownership structure update rather than providing a strong catalyst for a 'buy' or 'sell' recommendation. A 'hold' position is prudent until more comprehensive company performance data is available.

Keywords

Artelo Biosciences, ARTL, Schedule 13D, Daniel S. Farb, beneficial ownership, common stock, warrants, SEC filing, biotechnology, investment